Windlas Biotech Limited

Rs 712.20

Closing Price Date 05-Jul-2024

BSE 543329

Category Healthcare

SC NAME:

WINDLAS

Market Cap:

1,489

High / Low:

794 / 306

Stock P/E:

25.6

Book Value:

216

Dividend Yield:

0.55

ROCE:

18.1

ROE:

13.6

Face Value:

5.00

PEG Ratio:

1.20

EVEBITDA:

16.0

Debt:

3.64

CMP / FCF:

78.9

Debt to equity:

0.01

NP Ann:

58.1

High price all time:

794

Piotroski score:

8.00

Graham Number:

369

No. Eq. Shares:

2.09

Net CF:

1.56

Net profit:

58.1

Price to book value:

3.29

Interest Coverage:

71.0

Low price all time:

203

Reserves:

440

Industry PE:

27.5

Free Cash Flow:

71.3

Short Description

Windlas Biotech Limited specializes in Pharmaceuticals within the Healthcare sector.

Long Description

Windlas Biotech Limited, with Security Code 543329, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

Data Table

Quarterly Table

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2024-01-01	2024-03-31	1712.85	169.49	1757.25	8.12	51.39	44.4	35.36	225.63
2023-10-01	2023-12-31	1,622.13	150.98	1,653.77	7.26	-18.65	31.64	-33.89	198.07
2023-10-01	2023-12-31	1,622.13	150.98	1,653.77	7.26	-18.65	31.64	-33.89	198.07
2023-07-01	2023-09-30	1,526.72	140.31	1,559.12	6.75	-22.64	32.40	-33.30	183.12
2023-07-01	2023-09-30	1,526.72	140.31	1,559.12	6.75	-22.64	32.40	-33.30	183.12
2023-04-01	2023-06-30	1,447.86	120.65	1,474.10	5.79	-	26.24	-31.89	163.40
2023-04-01	2023-06-30	1,447.86	120.66	1,474.10	5.79	-	26.24	-31.89	163.41
2023-01-01	2023-03-31	1,407.13	114.44	1,430.47	5.37	-	23.34	-35.68	150.41
2023-01-01	2023-03-31	1,407.13	114.48	1,430.47	5.37	-	23.34	-35.68	150.45
2022-10-01	2022-12-31	1,197.04	91.88	1,218.66	4.23	-122.91	21.62	-31.35	128.19
2022-10-01	2022-12-31	1,197.04	91.88	1,218.66	4.24	-122.91	21.62	-31.35	128.19
2022-07-01	2022-09-30	1,327.30	121.94	1,353.41	5.59	-145.34	26.11	-29.05	156.35
2022-07-01	2022-09-30	1,327.30	121.94	1,353.41	5.59	-145.34	26.11	-29.05	156.35
2022-04-01	2022-06-30	1,199.36	98.00	1,227.94	4.50	-130.96	28.58	-27.56	135.44
2022-04-01	2022-06-30	1,199.36	98.00	1,227.94	4.50	-130.96	28.58	-27.56	135.44
2022-01-01	2022-03-31	1,221.31	147.88	1,251.36	6.97	-15.57	30.05	-29.02	136.56
2022-01-01	2022-03-31	1,221.31	152.33	1,251.36	7.19	-16.38	30.05	-29.02	141.00
2021-10-01	2021-12-31	1,175.91	83.14	1,193.84	3.81	-119.22	17.93	-31.45	114.79
2021-10-01	2021-12-31	1,175.91	83.15	1,193.84	4.14	-119.21	17.93	-31.45	114.80
2021-07-01	2021-09-30	1,152.52	83.00	1,164.71	4.10	-120.28	12.19	-30.75	108.63
2021-07-01	2021-09-30	1,152.52	83.26	1,164.71	4.12	-120.01	12.19	-30.75	108.90
2021-04-01	2021-06-30	1,109.56	66.87	1,116.45	3.66	-110.98	6.89	-30.25	95.67
2021-04-01	2021-06-30	1,109.56	66.87	1,116.45	3.66	-110.98	6.89	-30.25	95.67

Date Begin	Date End	Net Sales	Net Profit	Total Income	Diluted EPS for continuing operation	Other Expenses	Other Income	Depreciation and amortisation expense	Profit (+)/ Loss (-) from Ordinary Activities before Tax
2024-01-01	2024-03-31	1712.85	169.49	1757.25	8.12	51.39	44.4	35.36	225.63
2023-10-01	2023-12-31	1,622.13	150.98	1,653.77	7.26	-18.65	31.64	-33.89	198.07
2023-10-01	2023-12-31	1,622.13	150.98	1,653.77	7.26	-18.65	31.64	-33.89	198.07
2023-07-01	2023-09-30	1,526.72	140.31	1,559.12	6.75	-22.64	32.40	-33.30	183.12

Compounded Data

Standalone

Consolidated

Compounded Sales Growth
10 Years:	0%
5 Years:	17%
3 Years:	14%
TTM:	23%

Compounded Profit Growth
10 Years:	0%
5 Years:	21%
3 Years:	44%
TTM:	38%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	142%

Compounded Sales Growth
10 Years:	0%
5 Years:	15%
3 Years:	14%
TTM:	23%

Compounded Profit Growth
10 Years:	0%
5 Years:	21%
3 Years:	23%
TTM:	39%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	142%

Latest News

Windlas Biotech Announces Positive Results from Phase III Clinical Trial of WP1066 in Management of Knee Osteoarthritis
Windlas Biotech Limited (NSE: WINDLAS), a leading Indian pharmaceutical company, has announced positive results from a Phase III clinical trial evaluating the efficacy and safety of its novel drug candidate, WP1066, in the management of knee osteoarthritis.
Windlas Biotech announces Dr. B. S. Jairam as new CEO and Managing Director
Windlas Biotech Limited, a leading Indian pharmaceutical company, announced the appointment of Dr. B. S. Jairam as its new Chief Executive Officer (CEO) and Managing Director (MD), effective from August 1, 2023. Dr. Jairam brings over three decades of extensive experience in the pharmaceutical industry and has a proven track record of leadership and innovation.
Windlas Biotech receives USFDA approval for generic drug
Windlas Biotech has received approval from the United States Food and Drug Administration (USFDA) for its generic version of a popular drug. This approval marks a significant milestone for the company as it strengthens its position in the US market.
Windlas Biotech partners with global healthcare leader
Windlas Biotech has announced a strategic partnership with a leading global healthcare company. This partnership will combine the strengths of both companies to bring new and innovative healthcare solutions to patients worldwide.
Windlas Biotech Partners with Suven Life Sciences to Commercialize Novel Molecules for CNS Disorders
Windlas Biotech Limited (NSE: WINDLAS), a leading Indian pharmaceutical company, has entered into a strategic partnership with Suven Life Sciences Limited (BSE: 532381), a leading Indian biotechnology company, to commercialize novel molecules for the treatment of central nervous system (CNS) disorders.
Windlas Biotech Receives ANDA Approval for Generic Gabapentin Tablets from USFDA
Windlas Biotech Limited (NSE: WINDLAS) announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Gabapentin Tablets USP, 100 mg, 300 mg, and 400 mg.